An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
SaponiQx Announces Breakthrough in Scaling Up of STIMULON™ Cultured Plant Cell Adjuvant
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Agenus Inc. (NASDAQ: AGEN) achieves a milestone in scaling the production of its STIMULON cultured plant cell (cpc) QS-21 adjuvant, designed to amplify the efficiency and endurance of vaccines. The breakthrough includes successful production of STIMULON cpcQS-21 with confirmed biochemical comparability to traditional bark extract-derived adjuvants. SaponiQx has submitted a Master File (MF) to the U.S. FDA, maintaining regulatory compliance. Ongoing collaboration with Ginkgo Bioworks aims to drive innovation in SaponiQx's adjuvant pipeline through generative molecular design.
Positive
None.
Negative
None.
Successful production of STIMULON™ cpcQS-21, a cultured plant cell adjuvant with confirmed biochemical comparability to traditional bark extract-derived adjuvant
Submission of Master File (MF) for STIMULON cpcQS-21 to the U.S. FDA for reference by partners as part of regulatory submissions
Ongoing collaboration with Ginkgo Bioworks to drive innovation in SaponiQx's adjuvant pipeline through generative molecular design
LEXINGTON, Mass.--(BUSINESS WIRE)--
SaponiQx, the adjuvant subsidiary of Agenus Inc. (NASDAQ: AGEN), specializing in saponin-based adjuvant discovery and manufacturing, has achieved a milestone in scaling the production of its STIMULON cultured plant cell (cpc) QS-21 adjuvant, designed to amplify the efficiency and endurance of vaccines. This cultured plant cell adjuvant is building upon SaponiQx’s expertise with its proprietary adjuvant STIMULON QS-21, a critical component of effective vaccines, including GSK’s Shingrix (Zoster Vaccine Recombinant, Adjuvanted) and Arexvy (Respiratory Syncytial Virus, Adjuvanted).
"SaponiQx is furthering its trailblazing work in adjuvant and vaccine discovery, as well as mass manufacturing," said Chandresh Harjivan, SaponiQx's President and Chief Operating Officer. "Building on Agenus’ vast experience with STIMULON, SaponiQx aims to achieve global-scale manufacturing, creating a consistent and sustainable supply by employing advanced plant and engineered cell-production techniques. Additionally, we are developing a diverse range of next-generation saponin-based adjuvants to meet the demands of existing and emerging infectious diseases."
Progress Highlights:
Breakthrough in Production: SaponiQx has successfully manufactured STIMULON cpcQS-21, showing biochemical comparability to traditional bark extract-derived adjuvants. This method eliminates the need for extraction from the Chilean soap tree bark, enabling scalable and cost-effective production. This innovation also promises consistent quality and resolves potential supply issues.
Regulatory Compliance: SaponiQx is manufacturing STIMULON cpcQS-21 in accordance with Good Manufacturing Practice (GMP) standards and has submitted a master file to the U.S. FDA to enable Investigational New Drug (IND) sponsors to reference the data as part of their regulatory submissions.
Ongoing Collaboration: Partnering with Ginkgo Bioworks, SaponiQx is developing a collection of new saponin-based adjuvants, employing generative molecular design and artificial intelligence. This alliance aims to deliver tailored, potent adjuvants cost-effectively and at a scale suitable for global vaccination programs.
About SaponiQx
Founded in 2021, SaponiQx, a subsidiary of Agenus Inc., stands at the forefront of saponin-based adjuvant discovery and manufacturing. Its mission is to provide scalable and affordable vaccine adjuvants to enhance global health. Its proprietary adjuvant, STIMULON QS-21, forms an integral part of the AS01 adjuvant used in several leading vaccines.
STIMULON is a trademark of Agenus Inc., the parent company of SaponiQx Inc. Shingrix and Arexvy are trademarks of GlaxoSmithKline Biologicals, S.A.
Forward-Looking Statements
This press release includes forward-looking statements, subject to risks and uncertainties, concerning the development of vaccines and adjuvants. Refer to the Risk Factors in Agenus’ latest Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the SEC for a detailed discussion of these risks.
What is the milestone achieved by Agenus Inc. (NASDAQ: AGEN)?
Agenus Inc. (NASDAQ: AGEN) has achieved a milestone in scaling the production of its STIMULON cultured plant cell (cpc) QS-21 adjuvant, designed to amplify the efficiency and endurance of vaccines.
What is the significance of the successful production of STIMULON cpcQS-21?
The successful production of STIMULON cpcQS-21 shows biochemical comparability to traditional bark extract-derived adjuvants, promising scalable and cost-effective production with consistent quality and resolving potential supply issues.
What regulatory steps have been taken by SaponiQx?
SaponiQx has submitted a Master File (MF) to the U.S. FDA, ensuring regulatory compliance and enabling Investigational New Drug (IND) sponsors to reference the data as part of their regulatory submissions.
What is the focus of the ongoing collaboration with Ginkgo Bioworks?
The ongoing collaboration with Ginkgo Bioworks aims to drive innovation in SaponiQx's adjuvant pipeline through generative molecular design and artificial intelligence.
agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody